Known as Fenofibric Acid Delayed-release Capsules, 45mg and 135mg is indicated for patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their low-density lipoprotein cholesterol goal.
New generic product is used as an adjunct to diet in combination with a statin to lessen triglyceride and enhance high-density lipoprotein cholesterol.
The US Food and Drug Administration has approved the product’s abbreviated new drug application.
The sales of Fenofibric Acid Delayed-release Capsules, 45mg and 135mg, were around $553.6m for the 12 months ending on 31 March 2013 in the US, according to IMS Health data.